ÂÜÀòÂÒÂ×

Adam Savitz, MD, PhD, joined Alto Neuroscience after 10 years at Janssen R&D. At Janssen in Neurosciences, Adam led the paliperidone schizophrenia team to the approval of the 3-month long acting injectable in multiple markets as well as the pediatric indication in Europe. He then led the clinical development of an antidepressant with a novel mechanism of action from phase 2 into phase 3 focused on an FDA supported unique indication. ​​He was also the clinical strategic leader across the Mood Disorder pipeline, focusing on the transition of medications from early to late development. He led the Janssen Neurosciences’ efforts in two public-private precision psychiatry consortia (IMI’s EU-PEARL and fNIH’s AMP-Sz) and collaborated with internal and external groups on a variety of projects including genetics, scale assessment, and in vitro diagnostics, resulting in multiple publications.

Prior to Janssen, Adam was on the faculty at Weill Cornell Medical College where he continues on the voluntary faculty. At Weill Cornell, he led the Second Chance Program, a specialized inpatient psychiatric program for chronically institutionalized patients with psychotic disorders and was Directory of Clinical Schizophrenia Research. He completed his psychiatry training and served on the staff at Massachusetts General Hospital and his MD/PhD (molecular biology) at UCLA.